Home | Welcome to Contract Pharma   
Last Updated Monday, May 20 2013
Print RSS Feed

Breaking News

Related Searches: Promotions & Moves •
LifeCycle Pharma A/S

November 30, 2007
Hans Christian Teisen has been named senior vice president and chief financial officer at LifeCycle Pharma. He replaces Michael Wolff Jensen, executive vice president and chief financial officer, who has decided to leave the company, effective March…  Read More »
IVT, Dalton Scale Up Vax Platform

November 30, 2007
ImmunoVaccine Technologies Inc. (IVT) has successfully scaled-up the manufacturing process for its vaccine platform, Vaccimax. The manufacturing development was performed by Dalton Pharma Services. VacciMax is a vaccine-enhancement platform compri…  Read More »
Sanofi Bumps Up Regeneron Stake

November 29, 2007
Regeneron Pharmaceuticals and Sanofi-Aventis have entered a new collaboration, which will include a greater SA stake in the biopharma. The companies will work to discover, develop, and commercialize fully-human therapeutic antibodies utilizing Regene…  Read More »
QLT Considers Selloff

November 28, 2007
QLT Inc. has formed a Special Committee to "review all strategic alternatives available," according to a company statement. The committee, comprised of three independent directors from the board, has appointed Morrison & Foerster, LLP a…  Read More »
Baxter, DynPort Receive HHS Flu Vax Funds

November 28, 2007
DynPort Vaccine Co. and Baxter International have received a $201.2 million contract modification from the U.S. Department of Health and Human Services (HHS) for the development of Baxter's cell-cultured seasonal and pandemic influenza candidate vacc…  Read More »
Gene Logic

November 28, 2007
Bethany Mancilla has been promoted to senior vice president, business development at Gene Logic, where she will lead the company's partnering and licensing efforts. Since July 2004, Ms. Mancilla has been involved in the formation and development of G…  Read More »
GSK, Pharmacopeia Pact Yields New Leads

November 27, 2007
Pharmacopeia has identified a pair of new lead compounds for advancement in its alliance with GlaxoSmithKline. The first of the lead compounds forms the basis of a new lead optimization program focused on identifying a treatment for respiratory disea…  Read More »
Valeant Readies RESTORE2 Trial

November 27, 2007
Valeant Pharmaceuticals has reached full enrollment in RESTORE2, its second Phase III study of retigabine in the treatment of epilepsy. Retigabine is a first-in-class neuronal potassium channel opener demonstrated to be effective in a recently publis…  Read More »
Genzyme, Fovea Collaborate in Retinal Disease

November 27, 2007
Genzyme and Fovea Pharmaceuticals SA have entered into a collaborative research pact centered on Fovea's proprietary high content technology platform that allows the identification of new targets involved in photoreceptor degeneration in retinal dyst…  Read More »
Santen Begins Trials with Oakwood Technology

November 26, 2007
Santen Pharmaceutical Co., Ltd., of Osaka, Japan has begun Phase I/IIa trials of DE-102, its steroidal treatment for macular edema, employing Oakwood Laboratories' Chroniject™ sustained release delivery technology. The product's microsphere for…  Read More »
Akorn Gains Vaccine sBLA Approval

November 26, 2007
Akorn, Inc. has received approval from the FDA for its supplemental BLA for a unit-dose preservative-free Tetanus Diphtheria vaccine. The company expects to launch the vaccine in 1Q08. In March 2007, Akorn announced that it had entered into an exc…  Read More »
MedImmune Starts RA Trials

November 26, 2007
MedImmune has begun dosing patients in the first Phase I trial of CAM- 3001, a fully human MAb targeting the alpha subunit of the granulocyte-macrophage colony stimulating factor receptor (GM-CSFR). The study is designed to evaluate the safety and to…  Read More »
GSK to Acquire Reliant Pharmaceuticals

November 21, 2007
GlaxoSmithKline has entered an agreement to acquire Reliant Pharmaceuticals Inc. for $1.65 billion in cash. Reliant is a privately held specialty pharma company focused on cardiovascular therapies. In the nine months ending September 30, 2007, the co…  Read More »
Patheon

November 21, 2007
Wesley P. Wheeler has been appointed chief executive officer of Patheon Inc., effective December 10, 2007. Mr. Wheeler will succeed Riccardo Trecroce, who plans to leave the company in 2008, following a transition period. "With Patheon's r…  Read More »
Merck Suspends Enrollment in Cancer Trials

November 21, 2007
Merck has suspended enrollment in clinical trials for the investigational Aurora kinase inhibitor, MK-0457, pending analysis of all efficacy and safety data for the drug. The decision was based on preliminary safety data, in which a clinical safety f…  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On
Please visit our sister sites: